News
-
-
PRESS RELEASE
HBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 1.25 billion
HBM Healthcare Investments announces Yellow Jersey Therapeutics acquisition by Johnson & Johnson for USD 1.25 billion. Transaction increases NAV per HBM share by CHF 8.70 (+3.5%) with expected cash inflow of USD 78 million -
-
PRESS RELEASE
HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America
Swixx BioPharma, a portfolio company of HBM Healthcare Investments, expands into Latin America with acquisition of Laboratorios Biopas Group, boosting sales and profits -
-
PRESS RELEASE
HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America
HBM Healthcare Investments' portfolio company Swixx BioPharma acquires Laboratorios Biopas Group in Latin America, boosting sales and profits. The strategic acquisition expands Swixx's footprint and market presence -
-
-
-
PRESS RELEASE
HBM Healthcare Investments achieves a balanced result in the 2023/2024 financial year
HBM Healthcare Investments almost broke even in the 2023/2024 financial year with a slight loss of CHF 1 million. Mixed portfolio performance with a 0.3% increase in NAV. Unfavourable currency developments affected results. Board proposes unchanged par value repayment of CHF 7.50 per share
